Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Cancer: Page 3
Exact Sciences shares rise on 24% Q1 revenue growth, higher 2023 guidance
The firm is seeing a “dramatic increase in the electronic ordering rate” at health systems, which is helping grow sales, its CEO Kevin Conroy said.
May 10, 2023
Genetic testing firms Sophia, Fulgent, Veracyte report Q1 financial results
Veracyte last Thursday reported first quarter revenue of $82.4 million, up 22% compared to the first quarter of 2022. The company grew total test volume to 28,788, an increase of 24% compared to the first quarter of 2022.
May 9, 2023
Red flags signal early-onset colorectal cancer
Recognizing four red flags for early-onset colorectal cancer may be key to earlier detection, diagnosis, and improved survival among younger patients.
May 5, 2023
Calculator identifies myeloma patients with favorable prognoses
An open-access calculator tool may help identify patients with more benign multiple forms of multiple myeloma, and help individualize their treatment.
May 5, 2023
Tempus granted FDA premarket approval for colorectal cancer CDx
The NGS test detects substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs) and insertion and deletion alterations (INDELs) in 648 genes, as well as microsatellite instability (MSI) status.
May 1, 2023
Texas Tech researchers use machine learning to classify cancer cells, predict metastatic potential
A deep-learning network model in a study analyzed cancer cell images to classify them by type, enabling prediction of their metastatic potential.
May 2, 2023
EarlySign colon cancer algorithm to be offered in Roche Navify suite of digital medical algorithms
The addition of ColonFlag to the Navify suite is the latest development in an ongoing collaboration between EarlySign and Roche for early lung and gastric cancer detection.
May 1, 2023
Cancer patients’ molecular testing, treatment varies across oncology practices in study
Access to molecular testing and targeted therapy for non-small cell lung cancer and colorectal cancer patients varies across oncology practices.
April 28, 2023
Promis Diagnostics nabs FDA breakthrough device designation for bladder cancer test
The EarlyTect BCD test qualitatively detects an epigenetic biomarker, PENK methylation, associated with bladder cancer in the urine DNA of patients with hematuria.
April 28, 2023
Bladder cancer biomarker signature could identify likely responders to checkpoint inhibitors
A diagnostic tool that identifies the patients most likely to respond to checkpoint inhibitors could enable physicians to determine the best treatment for each individual.
April 27, 2023
Simple CRISPR urine test may enable early cancer diagnosis
Researchers have designed a new nanoparticle sensor that could enable early diagnosis of cancer with a simple urine analysis.
April 26, 2023
Mainz Biomed partners with Instituto de Microecologia for at-home CRC test distribution in Spain, Portugal
The Instituto de Microecologia in Madrid will partner with Mainz to market the CRC detection test to physicians and their patients in the Iberian Peninsula.
April 26, 2023
Previous Page
Page 3 of 86
Next Page
